Drug Profile

Veliparib - Abbvie

Alternative Names: ABT-888; NSC-737664

Latest Information Update: 30 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Abbott Laboratories
Developer Abbott Laboratories; AbbVie
Class Amides; Antineoplastics; Benzimidazoles; Pyrrolidines; Small molecules
Mechanism of Action Poly(ADP-ribose) polymerase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Phase III Fallopian tube cancer; HER2 negative breast cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer
Phase II/III Glioblastoma
Phase II Brain metastases; Breast cancer; Colorectal cancer; Germ cell and embryonal neoplasms; Germ cell cancer; Malignant melanoma; Pancreatic cancer; Rectal cancer; Solid tumours; Testicular cancer
Phase I/II Glioma; Head and neck cancer; Small cell lung cancer
No development reported Lymphoma; Multiple myeloma; Prostate cancer
Discontinued Liver cancer

21 Mar 2025 National Cancer Institute completes a phase II trial in Breast cancer and Triple-negative breast cancer (Combination therapy, Second-line therapy or greater) in Puerto Rico and USA (PO, Capsule) (NCT02595905)
05 Apr 2024 Efficacy data from the phase II I-SPY trial in Breast cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
25 Jan 2024 AbbVie completes a phase III trial in HER2-negative-breast-cancer (Combination therapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease) in USA, Austria, Argentina, Australia, Belgium, Finland, Portugal, Hungary, Latvia, Spain, Puerto Rico, Ukraine, Turkey, Taiwan, South Africa, Singapore, Russia, Romania, Poland, Norway, the Netherlands, Mexico, Lithuania, South Korea, France, Israel, Germany, Estonia, Denmark, Czech Republic, Colombia, Chile, Canada, Belarus, the UK, Sweden and Italy(PO) (NCT02163694) (EudraCT2014-000345-70)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com